Senté develops clinically tested, medical-grade skincare built around two proprietary GAG analog technologies: low molecular weight Heparan Sulfate Analog (HSA) and Dermatan Sulfate and Chondroitin Sulfate (DECO). Its formulations aim to restore skin biology, support collagen and elastin structure, and improve appearance of photodamaged skin while being suitable for sensitive skin and all skin tones. The company distributes primarily through physician-dispensed channels and e-commerce and said it will use new capital to accelerate growth and expand those channels. Leadership changes announced alongside the financing include promotion of Zubin Meshginpoosh to CEO and appointment of co-founder Kleanthis G. Xanthopoulos as Executive Chairman. Senté emphasizes scientific rigor, clinical integrity, and partnerships with medical professionals in pursuing regenerative skincare innovation.

Total raised

$5M

Funding rounds

2

Latest round

Series C

Latest activity

Jun 2014